|Bid||0.00 x 1200|
|Ask||0.00 x 1100|
|Day's range||111.02 - 112.31|
|52-week range||101.24 - 142.60|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||23.36|
|Earnings date||18 Oct 2022 - 24 Oct 2022|
|Forward dividend & yield||1.88 (1.68%)|
|Ex-dividend date||14 Jul 2022|
|1y target est||127.91|
Thermo Fisher's (TMO) novel Applied Biosystems HIV-1 Genotyping Kit will aid in the global efforts to monitor the evolution of HIV.
With 50 consecutive years of dividend growth, healthcare giant Abbott Laboratories (NYSE: ABT) is a Dividend King. In late July, Abbott Laboratories shared its financial results for the second quarter ended June 30. As was also the case in the previous quarter, Abbott's nutrition segment was the only segment to not log year-over-year sales growth.
U.S. healthcare company Abbott Laboratories plans to hire 1,000 more people in Ireland in one of the biggest job announcements this year in the country's booming multinational sector, state investment agency IDA Ireland said on Friday. Abbott, which is one of the largest multinational employers in Ireland with 5,000 staff, will expand its manufacturing facilities in the north west county of Donegal and build a new plant at the other end of the country in Kilkenny. Confirming the $450 million investment, Abbott's senior vice-president for diabetes care, Jared Watkin, told the Irish Times that choosing Ireland for its increased production of devices that monitor glucose levels made strategic sense.